Physician profile
James Hanna
NPI 1962818583
$1,584.64
in general payments reported to CMS, 2019-2025
24 companies · $906 in 2025
The $906 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.64 · 2020: $13.05 · 2021: $61.55 · 2023: $24.61 · 2024: $567 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421 · Education: $77.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.95 |
| Education | $77.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $303.90 | 2024-2025 | |
| Travere Therapeutics, INC. | $189.68 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $144.85 | 2024-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $126.49 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.77 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $109.70 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $97.42 | 2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $79.54 | 2024-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $77.45 | 2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $41.45 | 2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $37.30 | 2025 | Lupkynis |
| Amgen INC. | $36.88 | 2024 | Tavneos |
| E.R. Squibb & Sons, L.L.C. | $33.61 | 2021 | |
| Scpharmaceuticals INC. | $23.07 | 2025 | |
| Ardelyx, INC. | $22.00 | 2025 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $18.70 | 2025 | |
| Glaxosmithkline, LLC. | $18.12 | 2025 | Benlysta |
| Daiichi Sankyo INC. | $17.28 | 2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $15.17 | 2021 | |
| Vifor Pharma, INC. | $14.63 | 2025 | Veltassa |
| Akebia Therapeutics INC | $14.17 | 2024 | Auryxia |
| Allergan, INC. | $13.05 | 2020 | |
| Boston Scientific Corporation | $12.77 | 2021 | |
| Pfizer INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.